SEP-4199

SEP-4199, also known as non-racemic amisulpride, is a non-racemic form of amisulpride which is under development for the treatment of bipolar depression.^[1][2][3] It is taken by mouth.^[1]

SEP-4199

Aramisulpride (R)-amisulpride
Esamisulpride (S)-amisulpride
Clinical data
Other names	SEP4199; Non-racemic amisulpride; Aramisulpride/esamisulpride; Esamisulpride/aramisulpride
Routes of administration	Oral[1]
Legal status
Legal status	Investigational
Identifiers
CAS Number	71675-90-6 (R) 71675-92-8 (S)
PubChem CID	5746246 3055076
UNII	B4J10KD2KI ES3TWM82E8
Chemical and physical data
Formula	C17H27N3O4S
Molar mass	369.48 g·mol−1

It was developed to have higher binding affinity for the serotonin 5-HT₇ receptor and lower affinity for the dopamine D₂ receptor compared to conventional racemic amisulpride.^[1][3][4][5] It contains the (R)- and (S)-enantiomers of amisulpride (aramisulpride and esamisulpride) in an 85:15 ratio rather than a 50:50 ratio.^[3] The modification is hoped to give the compound improved effectiveness and fewer side effects.^[3][6]

If approved, it would be the first form of amisulpride approved in the United States for psychiatric indications.^[5] It is in phase 3 clinical trials for bipolar depression as of December 2023.^[1][7] Its development was reported to have been discontinued in certain countries including the United States and Japan in November and December 2023.^[1] Sources are conflicting on whether it remains in development.^[1][2]

See also

• N-Methylamisulpride (LB-102)